World Orphan Drug Alliance – partnering with Decisive Consulting to broaden access capability
14 Nov 2022
Orphan DrugClinical Study
World Orphan Drug Alliance (WODA), a global alliance of full-service regional distributors for orphan drugs, welcomes Decisive Consulting into the Alliance network.
Decisive Consulting approaches commercial strategy with an “access first” lens, hands-on delivery of sustainable patient access through Early Access Programs to robust global pricing and reimbursement.
Dubai, Moscow, Ljubljana, Sao Paulo, Zurich, London, November 14, 2022 – WODA members (EffRx Pharmaceuticals, Medis, Orpharm, OrphanDC G, and Vector Pharma), are pleased to announce the addition of Decisive Consulting to the Alliance network. With a highly experienced team, Decisive Consulting has capabilities to solve many challenging issues related to pricing, market access, portfolio design and launch strategy.
WODA aims to provide comprehensive support to pharmaceutical and biotech companies working in rare diseases, oncology and highly specialized therapeutics portfolio, starting from named patients programs through to full commercialization.
The access lens of Decisive Consulting will allow the Alliance to integrate vertically by offering existing and future partners a host of expanded services to navigate access, pricing and commercialisation strategies, WODA will help partner companies deliver more innovative treatments to the patients that need them.
“The Decisive team has a wealth of experience across multiple therapeutic areas and geographies as well as being a leader in the rare and orphan space,” commented WODA Chairman Patrick Jordan. “Given that we operate primarily in the orphan space dealing with heterogenous, complex markets, the addition of Decisive’s consultancy services and know-how will be a value-add to our partners as well as an upgrade to the Alliance’s scope of services.”
In total, WODA covers 68 countries in the following regions: Turkey, Middle East and North Africa; Russia & CIS region; Central and Eastern Europe; Latin America; Switzerland. These regions cover approximately 1.6 billion people. This is very complementary to Decisive’ s commercial strategy and access focused expertise that extends globally, enhanced via the alliance.
“We know how complex it is to bringing innovative medicines and technologies to market, in Europe and beyond. Our consultants have years of experience in delivering access, commercialisation and transformation strategies that lead our clients to achieve their commercial aspirations”, said Esther Nzenza, CEO, Decisive Consulting.
“By combining our first-hand knowledge and expertise, we thrive on helping companies navigate the complexities of getting to market including access strategies (reimbursement to Named Patient Programmes), policy setting, pricing and launch readiness. We are pleased to offer our partners a more global view by being part of the WODA network, as we all work together to deliver access to life-saving and life altering treatments to patients around the world.”
About WODA Founding Members:
EffRx Pharmaceuticals is a Switzerland based company focused on the late-stage development and commercialization of prescription medications for niche and orphan indications.
Medis based in Slovenia is the commercialization partner of choice for innovative pharmaceutical and biotech companies seeking strong business growth in Central and Eastern Europe.
Orpharm is a Moscow based full-service distributor covering Russia and the Commonwealth of Independent States (CIS).
OrphanDC G based in Sao Paolo, Brazil acts as a partner for biotech companies in Latin America. They focus on supporting their clients from the clinical development stage throughout the product lifecycle.
Vector Pharma is a Dubai based full-service distributor covering Middle East, North Africa and Turkey.
More about WODA:
More about Decisive Consulting:
Contact for media:
Tina Vojnovic, tina.vojnovic@woda-alliance.com
Mobile: +38641744735
Janet Kettels, janet.kettels@decisiveconsulting.co.uk
Principle Consultant @Decisive Consulting
Mobile: +447738506476
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.